Read more

August 20, 2024
1 min read
Save

Top in ID: COVID-19 vaccine may lower risk for heart attack, stroke; update on mpox spread

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A study of people in the United Kingdom revealed that COVID-19 vaccination may reduce the risk for heart attack and stroke — possibly because the vaccine prevents the cardiovascular effects of SARS-CoV-2 infection, researchers said.

“This research further supports the large body of evidence on the safety of the COVID-19 vaccine program, which has been shown to provide protection against severe COVID-19 and saved millions of lives worldwide,” Samantha Ip, PhD, research associate in the University of Cambridge’s department of public health and primary care, said in a press release.

COVID vaccine draw
Findings from a U.K. study suggested that COVID-19 vaccination reduces the risk for heart attack and stroke, probably because the vaccine prevents the cardiovascular harms associated with infection. Image: Adobe Stock

It was the top story in infectious disease last week.

In another top story, WHO and the Africa CDC declared an outbreak of clade 1b mpox virus spreading through Africa to be a global public health emergency. The clade 1b virus is different from the clade 2 virus that was responsible for the 2022 global outbreak. No cases of clade 1b mpox have been reported in the United States.

Read these and more top stories in infectious disease below:

Study: Heart attack, stroke incidence lower after COVID-19 vaccination

The incidence of heart attack and stroke is lower among people who have been vaccinated against COVID-19 compared with before vaccination and people who have not received a vaccine, according to a study. Read more.

WHO declares mpox spread in Africa a global public health emergency

WHO declared the spread of mpox in Africa to be a global public health emergency. Read more.

Pfizer: RSV vaccine generates strong response in immunocompromised adults

A dose of Pfizer’s respiratory syncytial virus vaccine was well tolerated and generated a strong immune response among adults aged 59 years or younger, the company announced in a press release. Read more.

FDA authorizes marketing of at-home, over-the-counter syphilis test

The FDA has granted NOWDiagnostics authorization to market their at-home, over-the-counter antibody test that detects a potential syphilis infection, according to a press release. Read more.

Healio wins APEX award for report on CDC and FDA’s performance during COVID-19

Healio’s infectious diseases and pediatrics news teams received an APEX award for a 2023 report on the CDC and FDA’s performances during the COVID-19 pandemic, which was part of a larger series called “Life during COVID.” Read more.